Kailera Therapeutics raises $400M to advance next-generation obesity therapies

Boston, MA , October 1, 2024 (Globe Newswire) -- Kailera Therapeutics has launched as a clinical-stage biopharmaceutical company focused on obesity treatments, backed by $400 million in Series A financing. The company's lead product, KAI-9531, has demonstrated strong Phase 2 trial results, positioning it as a potential best-in-class therapy. With an experienced leadership team, Kailera aims to advance its innovative portfolio and has acquired global rights for key metabolic disease assets.

Read full article here.